Created: 03/25/2012 01:59:07 AM -
- Board type:
- Posts Today: 0
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
July 7, 2016 Pernix Therapeutics Announces Restructuring of Sales Force and Operations
June 16, 2016 Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
May 25, 2016 Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with BeadTek™
May 11, 2016 Pernix Therapeutics Announces CEO Transition
May 9, 2016 Pernix Therapeutics Overcomes Challenge to Treximet® ‘183 Patent
May 5, 2016 Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
April 28, 2016 Pernix Therapeutics to Report First Quarter 2016 Financial Results on Thursday, May 5, 2016
March 10, 2016 Pernix Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 2, 2016 Pernix Therapeutics Files Citizen Petition Following Issuance of U.S. Patent Number 9,265,760 (‘760 Patent) Covering Safety Information Related to Dosing Patients with Zohydro ER® with BeadTek™ CII
February 24, 2016 Pernix Therapeutics to Report Fourth Quarter and Full-Year 2015 Financial Results on Thursday, March 10, 2016
February 23, 2016 Pernix Therapeutics Announces the Issuance of New Orange Book Patent for Zohydro® ER With BeadTek™ CII
You must be logged in to give a plus1 award.